Cannabis Hyperemesis Syndrome Is Surging: What Every User Needs to Know
Advertisement
Cannabis is safer than alcohol. Cannabis is not physically addictive. Cannabis has no serious side effects.
These claims have circulated in cannabis culture for decades — and while the comparative safety profile of marijuana remains favorable, one condition is challenging the narrative that weed is consequence-free: Cannabinoid Hyperemesis Syndrome, or CHS.
Emergency department visits diagnosed as CHS increased from 4.4 per 100,000 visits in 2016 to 33.1 per 100,000 visits in 2020, according to a study published in JAMA Network Open. In Virginia alone, ER visits for the condition have jumped nearly 29 percent since 2020. And clinicians across the country report that they are seeing more CHS patients than ever before — many of whom had no idea the condition existed until they ended up in the hospital.
For a cannabis community built on openness and harm reduction, CHS deserves serious attention. Here's what the science says, who's at risk, and what you can do about it.
Key Takeaways
- Cannabinoid Hyperemesis Syndrome (CHS) emergency visits increased roughly 650 percent from 2016 to 2020, driven by higher-potency products and rising rates of daily cannabis use.
- CHS causes cyclical severe nausea, vomiting, and abdominal pain, with 85 percent of patients requiring at least one ER visit. The only proven cure is complete cessation of cannabis use.
- The cannabis community should embrace transparent education about CHS as a harm reduction priority, particularly for heavy users of high-potency concentrates and daily consumers.
Table of Contents
- What Is Cannabinoid Hyperemesis Syndrome?
- The Numbers Are Getting Worse
- Why Is CHS Increasing?
- The Diagnostic Challenge
- Treatment: The Only Cure Is Quitting
- What the Cannabis Community Should Do
What Is Cannabinoid Hyperemesis Syndrome?
CHS is a condition characterized by cyclical episodes of severe nausea, vomiting, and abdominal pain in people who use cannabis regularly. The syndrome typically develops after years of consistent cannabis use — most studies report an average onset after 10 to 12 years of chronic consumption — and can be debilitating enough to require emergency medical care.
The condition follows a distinctive pattern of three phases. The prodromal phase involves early morning nausea and abdominal discomfort, which many patients initially attempt to treat with more cannabis, unknowingly worsening the cycle. The hyperemetic phase brings intense, uncontrollable vomiting that can last for hours or days.
And the recovery phase begins when the patient stops using cannabis, with symptoms gradually resolving over days to weeks.
One of the most notable and unusual features of CHS is that patients often find temporary relief from symptoms through compulsive hot bathing or showering. This behavior is so characteristic of the condition that it is used as a diagnostic clue in emergency departments. The mechanism behind this relief is not fully understood, but researchers believe it may involve the activation of heat-sensitive receptors that interact with the body's endocannabinoid system [Quick Definition: Your body's built-in network of receptors that interact with cannabinoids].
The Numbers Are Getting Worse
The rise in CHS cases tracks closely with two converging trends: increasing cannabis potency and increasing rates of daily or near-daily use.
According to data published in JAMA Network Open, CHS prevalence in emergency departments increased roughly 650 percent between 2016 and 2020. While rates settled to 22.3 per 100,000 visits in 2022, they remain dramatically elevated compared to a decade ago.
State-level data tells a similar story. In Colorado, the incidence of cyclic vomiting — a key symptom of CHS — doubled after recreational cannabis legalization. Virginia has seen a 29 percent increase in CHS-related ER visits since 2020, with significant spikes also reported in Massachusetts, Northern California, and parts of North Carolina.
More than 40 percent of CHS patients report using cannabis five or more times a day, and many have used it heavily for five years or longer. The condition's impact extends beyond the vomiting episodes themselves: 85 percent of CHS patients report at least one ER visit related to their symptoms, and 44 percent report at least one hospitalization.
Why Is CHS Increasing?
Several factors are driving the surge in CHS cases. The most significant is the dramatic increase in cannabis potency over the past two decades. THC concentrations in flower have roughly tripled since the 1990s, and concentrates available today routinely exceed 80 to 90 percent THC.
Higher potency means greater activation of CB1 receptors in the gut, which researchers believe plays a central role in triggering CHS.
The normalization and legalization of cannabis has also contributed to higher rates of daily and heavy use. Nationally, nearly 7 percent of U.S. teens and adults met the criteria for cannabis use disorder in 2024, according to the National Survey on Drug Use and Health. Among adults aged 18 to 25, that figure rises to nearly 16 percent.
Rates of substance use disorder involving marijuana were 3.7 times higher in 2024 than in 2015.
The proliferation of high-potency consumption methods — particularly concentrates, dabs, and high-THC vape cartridges — may accelerate CHS development. While the condition has been documented in flower-only users, clinicians report that patients who use concentrates tend to present with more severe symptoms at younger ages.
The Diagnostic Challenge
CHS remains underdiagnosed for several reasons. First, many patients and healthcare providers are unaware of the condition's existence. Second, the symptoms of CHS overlap significantly with other gastrointestinal conditions, including cyclic vomiting syndrome (CVS), gastroparesis, and irritable bowel syndrome.
Third, patients may be reluctant to disclose their cannabis use to healthcare providers, particularly in states where marijuana remains illegal.
The result is a diagnostic odyssey that many CHS patients know all too well: repeated ER visits, extensive testing (often including CT scans, endoscopies, and blood work), and misdiagnosis. Some patients undergo unnecessary surgical procedures before CHS is identified as the cause. The average CHS patient visits the emergency department multiple times before receiving a correct diagnosis, at significant financial and personal cost.
Emergency medicine physicians have become increasingly skilled at identifying CHS, particularly through the hallmark symptom of compulsive hot bathing. But broader awareness among primary care providers, gastroenterologists, and patients themselves remains a critical gap.
Treatment: The Only Cure Is Quitting
Here is the part that many cannabis users do not want to hear: the only proven cure for CHS is complete cessation of cannabis use. No medication has been shown to reliably prevent CHS episodes in people who continue to consume cannabis.
During acute episodes, treatment focuses on symptom management: intravenous fluids for dehydration, anti-nausea medications (though traditional antiemetics often have limited effectiveness in CHS), and in some emergency departments, capsaicin cream applied to the abdomen, which appears to provide relief through a mechanism similar to hot bathing.
The recovery phase after quitting cannabis varies. Some patients report symptom resolution within two weeks, while others require one to three months for complete recovery. And the relapse rate is high: many patients who experience CHS return to cannabis use and subsequently experience recurrent episodes.
For the estimated 30 percent of cannabis users who develop some form of cannabis use disorder — and the subset of those who develop CHS — quitting is not a simple decision. Cannabis dependency is real, and withdrawal symptoms including insomnia, irritability, decreased appetite, and anxiety can make cessation challenging. Only 13 percent of people with cannabis use disorder receive any treatment annually, according to federal health survey data.
What the Cannabis Community Should Do
CHS is not an argument against cannabis legalization. It is an argument for informed consumption, honest public health messaging, and harm reduction within the cannabis community.
Dispensaries can play a role by educating budtenders about CHS and training them to recognize when customers may be at risk — particularly those purchasing high-potency concentrates in large quantities or reporting gastrointestinal symptoms. Product labels could include information about CHS risk, much as alcohol products carry warnings about health effects.
Cannabis media and advocacy organizations have a responsibility to discuss CHS openly rather than dismissing it as anti-cannabis propaganda. The condition is real, it is becoming more common, and the people it affects are overwhelmingly cannabis supporters who deserve accurate health information.
For individual consumers, the key message is moderation. CHS is strongly associated with heavy, daily use of high-potency products over extended periods. Consumers who use cannabis less frequently, opt for lower-potency products, or take regular tolerance breaks significantly reduce their risk.
If you experience persistent morning nausea, abdominal pain, or unexplained vomiting — especially if hot showers provide temporary relief — consider whether cannabis use may be a contributing factor and discuss it with your healthcare provider.
Pull-Quote Suggestions:
"Several factors are driving the surge in CHS cases."
"But broader awareness among primary care providers, gastroenterologists, and patients themselves remains a critical gap."
"In Virginia alone, ER visits for the condition have jumped nearly 29 percent since 2020."
Why It Matters: CHS emergency visits jumped 650% from 2016 to 2020. With cannabis potency rising and daily use at record highs, here's what every consumer should know.